Inotiv, Inc. Logo

Inotiv, Inc.

A CRO providing nonclinical drug development services and research models.

NOTV | US

Overview

Corporate Details

ISIN(s):
US09058M1036 (+1 more)
LEI:
Country:
United States of America
Address:
2701 KENT AVE, WEST LAFAYETTE

Description

Inotiv, Inc. is a contract research organization (CRO) providing a comprehensive range of nonclinical and analytical drug discovery and development services. Key service areas include general toxicology, pathology, histology, drug metabolism and pharmacokinetics (DMPK), and bioanalytical solutions. The company also offers specialized services such as digital pathology with AI-driven image analysis, monoclonal antibody production, and developmental and reproductive toxicology (DART) studies. In addition to its CRO services, Inotiv is a major provider of research models and related products. This includes a wide array of animal models, genetically engineered model services (GEMS), contract breeding, surgical services, and Teklad laboratory animal diets and bedding. Inotiv serves clients across the pharmaceutical, biotechnology, medical device, academic, and government sectors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-18 18:19
8-K
English 58.8 KB
2025-08-07 19:29
10-Q
English 1.9 MB
2025-08-07 09:49
8-K/A
English 132.9 KB
2025-08-06 18:13
8-K
English 130.7 KB
2025-08-04 18:28
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.3 KB
2025-07-18 18:33
424B7
English 92.9 KB
2025-07-03 18:30
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.3 KB
2025-06-04 18:05
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.3 KB
2025-06-04 09:37
8-K
English 54.2 KB
2025-06-02 12:26 English 6.9 KB
2025-05-29 10:25
8-K
English 7.6 MB
2025-05-07 22:28
10-Q
English 2.1 MB
2025-05-07 18:10
8-K
English 140.0 KB
2025-04-02 18:32
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
English 7.3 KB
2025-04-01 20:33 English 6.9 KB

Automate Your Workflow. Get a real-time feed of all Inotiv, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inotiv, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inotiv, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.